← All trials
NCT06937593
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2025
- Primary completion
- Jan 6, 2026
- Completion date
- Feb 13, 2026
- First posted
- Apr 22, 2025
- Last posted
- Aug 21, 2025
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Visterra, Inc.Lead sponsor
- Anaheim Clinical TrialsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.